A study of incidence of molecular mutations in newly diagnosed acute myeloid leukemia (AML) patients by Next-generation sequencing technique
- Conditions
- ewly diagnosed acute myeloid leukemia aged greater than 18 yearsAcute myeloid leukemia, molecular, incidence, next-generation sequencing
- Registration Number
- TCTR20190227003
- Lead Sponsor
- The organization takes responsibility for initiating a study.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 139
Inclusion Criteria
Thai newly diagnosed AML patients aged greater than 18 years who signed consent in Protocol title The newly diagnosed acute myeloid leukemia registry and ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sample collections for further investigating about molecular mutations: Protocol number 793/2560(EC2) and had extracted DNA and RNA samples
Exclusion Criteria
1. A patient who has poor extracted DNA quality
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of molecular mutations in Thai adult newly diagnosed AML patients by NGS technique 1 year next-generation sequencing (targeted gene sequencing: Illumina machine)
- Secondary Outcome Measures
Name Time Method To evaluate the clinical outcome in Thai adult AML patients considering molecular mutations 1 year case record form comparing with genetic results by Illumina machine